Trial Profile
A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed Protocol EMR-700461-023 (ADDRESS II)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Atacicept (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors EMD Serono; Merck KGaA
- 24 Dec 2021 This trial has been completed in Czech Republic (Date of the global end of the trial : 09 Feb 2018), according to European Clinical Trials Database record.
- 06 Feb 2021 Results published in the Rheumatology
- 19 Mar 2019 Status changed to discontinued.